Market Place
Sourcing Support
FINTEPLA® (Fenfluramine) Results On Managing Seizures Published In Epilepsia
24 Jun 2024 //
PR NEWSWIRE
UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project
20 Jun 2024 //
BUSINESSWIRE
Acino completes acquisition of M8 Pharmaceuticals
04 Dec 2023 //
GLOBENEWSWIRE
UCB presents new data about the real-world experience of FINTEPLA
02 Dec 2023 //
PR NEWSWIRE
UCB Announces FINTEPLA® (fenfluramine) Oral Solution
17 Apr 2023 //
PR NEWSWIRE
CHMP recommends fenfluramine for LGS-associated seizures
20 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA
23 Nov 2022 //
PRNEWSWIRE
NICE recommends UCB’s Fintepla for Dravet syndrome
01 Jun 2022 //
PHARMATIMES
Fenfluramine found effective in preventing drop seizures from LGS
04 May 2022 //
EUROPEANPHARMACEUTICALREVIEW
JAMA Neurology Publishes PIII Study Results on Efficacy and Safety of FINTEPLA
02 May 2022 //
PRNEWSWIRE
UCB takes on Jazz in severe epilepsy with new Fintepla label approval
29 Mar 2022 //
PHARMAPHORUM
Zogenix To Present New Long-term Data on FINTEPLA in Lennox-Gastaut Syndrome
04 Mar 2022 //
GLOBENEWSWIRE
Zogenix Submits Type II Variation Application to (EMA) to the Use of FINTEPLA
20 Dec 2021 //
GLOBENEWSWIRE
Zogenix Submits Supplemental New Drug Application for FINTEPLA®
28 Sep 2021 //
GLOBENEWSWIRE
Zogenix Receives Orphan Drug Designation for FINTEPLA (Fenfluramine) in Japan
26 Aug 2021 //
GLOBENEWSWIRE
Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine)
27 Apr 2021 //
PRESS RELEASE
Zogenix introduces Fintepla oral solution in Germany for treatment of seizures
01 Feb 2021 //
PHARMABIZ
EU green light for Zogenix’s Fintepla
23 Dec 2020 //
PHARMATIMES
Zogenix gets EU marketing authorisation for anti-seizure drug
23 Dec 2020 //
PHARMAFILE
EU green light for Zogenix’s Fintepla
23 Dec 2020 //
RUTERS
Zogenix gets EU marketing authorisation for anti-seizure drug
23 Dec 2020 //
PHARMAFILE
Zogenix proposes $200M debt offering
22 Sep 2020 //
SEEKING ALPHA
Zogenix`s Fintepla successful in third pivotal study in severe type of epilepsy
09 Sep 2020 //
SEEKINGALPHA
FDA Approvals Roundup: Fintepla, Dojolvi, Phesgo
02 Jul 2020 //
RAPS
FDA Approves New Therapy for Dravet Syndrome
25 Jun 2020 //
FDA
So close, yet so far: Zogenix LGS trial succeeds, but results underwhelm
07 Feb 2020 //
ENDPTS
Zogenix Announces +ve Top-line Results Global Pivotal Ph3 Trial of FINTEPLA®
06 Feb 2020 //
PRESS RELEASE
The Lancet Publishes Ph 3 Trial Results for Zogenix Drug FINTEPLA
17 Dec 2019 //
GLOBE NEWSWIRE
French weight-loss pill scandal set for landmark trial
21 Sep 2019 //
REUTERS
Zogenix data blunder trips up FDA filing for epilepsy drug Fintepla
09 Apr 2019 //
FIERCE BIOTECH
Wall Street darling Zogenix shares positive PhIII data on rival drug
13 Jul 2018 //
ENDPTS
Chasing GW, Zogenix scores a win in second Dravet phase 3
12 Jul 2018 //
FIERCE BIOTECH
Is DEA Being Forced To Reschedule The CBD Compound?
12 Jul 2018 //
FORBES
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
05 Mar 2017 //
FINANCE YAHOO
